Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSI-202 is an intravenous lipid-based reformulation of the microtubule-stabilizing agent paclitaxel, developed by LipoSeuticals for the treatment of various cancers. Paclitaxel, a member of the taxane family, exerts its antineoplastic effect by binding to the beta-subunit of tubulin, which promotes the assembly of microtubules and inhibits their disassembly. This stabilization interferes with the dynamic instability of microtubules necessary for mitotic spindle formation, leading to cell cycle arrest in the G2/M phase and subsequent programmed cell death (apoptosis). LSI-202 utilizes a proprietary delivery system designed to enhance the solubility and pharmacological profile of paclitaxel, potentially reducing the side effects associated with conventional formulations that require surfactants like Cremophor EL.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LSI-202.